CDK4 Human shRNA Plasmid Kit (Locus ID 1019)

CAT#: TR320293

CDK4 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided

Specifications

Product Data

• Locus ID: 1019
• Synonyms: CMM3; PSK-J3
• Vector: pRS
• E. coli Selection: Ampicillin
• Mammalian Cell Selection: Puromycin
• Format: Retroviral plasmids
• Kit Components: CDK4 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 1019). 5µg purified plasmid DNA per construct
  29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
• RefSeq: NM_000075, NM_052984, NM_000075.1, NM_000075.2, NM_000075.3, BC005864, BC005864.2, BC003644, BC010153, BC015669, NM_000075.4
• UniProt ID: P11802
• Summary: The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). Mutations in this gene as well as in its related proteins including D-type cyclins, p16(INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers. Multiple polyadenylation sites of this gene have been reported. [provided by RefSeq, Jul 2008]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).